Literature DB >> 18303434

Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom.

Amarnath Jena1, Sangeeta Taneja, Vineet Talwar, Jai Bhagwan Sharma.   

Abstract

INTRODUCTION: Asymptomatic brain metastasis in lung cancer patients, if detected early have been reported to show survival benefit with treatment. These asymptomatic metastasis have been found to be smaller and less in number than those with symptoms. We however observed that many lung cancer patients bear a significant metastatic load in the brain irrespective of the stage or neurologic symptoms at the time of initial presentation.
MATERIAL AND METHODS: A retrospective study was conducted on 175 patients of proven non-small cell lung cancer to assess the patterns of brain metastasis in the two groups of patients, with and without neurologic symptoms. All patients had undergone screening magnetic resonance imaging for brain metastasis as an initial staging protocol. The patients with brain metastasis were divided into two groups: asymptomatic (group I) and symptomatic (group II). The lesions were studied with regards to the number, size, site, nature (solid with and without necrosis), and presence of perilesional edema and intralesional hemorrhage in both the groups in various stages of disease.
RESULTS: Brain metastasis was seen in 62 (31.3%) patients of whom 46.7% were neurologically asymptomatic. Patients (90.3%) with brain metastasis were in stage IV at the time of presentation. No statistically significant correlation was found between the two groups regarding the number of lesions (p = 0.554), size of lesion (p = 0.282), site of lesion (p = 0.344), nature of lesion (p = 0.280), presence of perilesional edema (p = 0.404), and presence or absence of intralesional hemorrhage (p = 0.09). In our study, brain metastases were present only in stages III and IV disease with no statistically significant difference in the lesion patterns.
CONCLUSION: The study reveals almost equal number of patients with brain metastasis in the symptomatic and asymptomatic groups with no significant difference in lesion patterns. We therefore conclude that although imaging surveillance of the brain for metastasis will detect asymptomatic metastasis early for early institution of appropriate therapy the prognosis in these patients would not solely depend on the presence or absence of symptoms and the pattern of lesion may have an influence on the patients' response to therapy and survival benefit specially for those asymptomatic patients with equally large metastatic load.

Entities:  

Mesh:

Year:  2008        PMID: 18303434     DOI: 10.1097/JTO.0b013e318161d775

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

1.  Incidence of seizure in adult patients with intracranial metastatic disease.

Authors:  Vivien Chan; Arjun Sahgal; Peter Egeto; Tom Schweizer; Sunit Das
Journal:  J Neurooncol       Date:  2016-11-22       Impact factor: 4.130

Review 2.  Epilepsy in brain metastasis: an emerging entity.

Authors:  Roberta Rudà; Francesca Mo; Alessia Pellerino
Journal:  Curr Treat Options Neurol       Date:  2020-02-08       Impact factor: 3.598

3.  Cerebral staging of lung cancer: is one single contrast-enhanced T1-weighted three-dimensional gradient-echo sequence sufficient?

Authors:  Mickaël Ohana; Mi-Young Jeung; Gauthier Bazille; Catherine Roy
Journal:  Neuroradiology       Date:  2014-05-15       Impact factor: 2.804

Review 4.  Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Authors:  Wenhui Wang; Xin Sun; Zhouguang Hui
Journal:  Oncol Res Treat       Date:  2019-09-17       Impact factor: 2.825

5.  Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India.

Authors:  Gundu Naresh; Prabhat Singh Malik; Sachin Khurana; Deepam Pushpam; Vinod Sharma; Mukesh Yadav; Deepali Jain; Sushmita Pathy
Journal:  JCO Glob Oncol       Date:  2021-04

6.  Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

Authors:  Marco D DiBonaventura; William Wong; Bijal Shah-Manek; Mathias Schulz
Journal:  Onco Targets Ther       Date:  2017-12-22       Impact factor: 4.147

7.  Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies.

Authors:  Ye Li; Guanqiao Jin; Danke Su
Journal:  Oncotarget       Date:  2017-05-30

8.  Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer.

Authors:  Garrett T Wasp; Christopher Del Prete; Jonathan A D Farrell; Konstantin H Dragnev; Gregory Russo; Graham T Atkins; Joseph D Phillips; Gabriel A Brooks
Journal:  Heliyon       Date:  2020-06-29

Review 9.  Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms.

Authors:  Frank Griesinger; Julia Roeper; Christoph Pöttgen; Kay C Willborn; Wilfried E E Eberhardt
Journal:  Oncotarget       Date:  2018-10-12

10.  Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma.

Authors:  Ho Yun Lee; Kyung Soo Lee; Byung-Tae Kim; Young-Seok Cho; Eun Jeong Lee; Chin A Yi; Myung Jin Chung; Tae Sung Kim; O Jung Kwon; Hojoong Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.